Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
Healios Joins Search For Acute Respiratory Distress Syndrome Treatment
• By Scrip Team
Generate a summary of this article
Listen to this article
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
A surgical mask showing a map of New York State: the US has overtaken China as the country with most COVID-19 cases, more than half of these in New York
A consortium of life sciences companies including leading pharma firms has announced a collaboration to speed up the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, working with the Bill & Melinda Gates Foundation.
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.